ASSESSMENT OF THE CLINICAL AND PATHOGENETIC MECHANISMS UNDERLYING THE PROGRESSION OF CHRONIC KIDNEY DISEASE AND METHODS FOR THEIR CORRECTION

Abstract

Introduction. Chronic kidney disease (CKD) is a global health priority due to its high prevalence (9-12% of the adult population), relentless progression, and early disability. The progression of CKD to end-stage renal disease (CKD stage 5) involves a complex interplay of hemodynamic, inflammatory, and metabolic factors.

References

1. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(Suppl 1):S1-S154.
2. Kalantar-Zadeh K., Fouque D. Nutritional Management of Chronic Kidney Disease. N Engl J Med. 2017;377:1765-1776.
3. Fouque D., et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in chronic kidney disease. Kidney Int. 2018;73:391-398.
4. Braliou G.G., et al. Renin-angiotensin system gene polymorphisms and chronic kidney disease: a systematic review and meta-analysis. J Renin Angiotensin Aldosterone Syst. 2014;15(4):465-478.
5. Heerspink H.J.L., et al. Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD). N Engl J Med. 2020;383:1436-1446.
6. Ikizler T.A., et al. KDOQI Clinical Practice Guideline for Nutrition in Chronic Kidney Disease: 2020 Update. Am J Kidney Dis. 2020;76(3 Suppl 1):S1-S107.